Workflow
Kodiak Sciences (KOD) Investor Presentation - Slideshow
KodiakKodiak(US:KOD)2023-04-04 17:37

Tarcocimab Tedromer Clinical Development - Tarcocimab tedromer aims for 5-6 month dosing intervals for the majority of patients with retinal vascular diseases, offering dosing flexibility [30, 31, 37] - Phase 1b study showed that ≥66% of wet AMD, DME, and RVO patients achieved Q24W (every 24 weeks) dosing [45] - Phase 2b/3 study in wet AMD showed 59% of patients achieved Q20W (every 20 weeks) dosing with tarcocimab, with comparable vision and anatomical outcomes vs aflibercept per label [45] - BEACON Phase 3 study in RVO met the primary endpoint of non-inferiority vs aflibercept dosed per label, doubling the treatment interval for all patients [45] - BEACON Phase 3 study in RVO demonstrated comparable vision and anatomical outcomes in BRVO patients, showing non-inferiority to aflibercept Q4W (every 4 weeks) [59] - In the BEACON Phase 3 RVO study, Tarcocimab demonstrated non-inferiority to aflibercept Q4W in all RVO patients, achieving comparable vision and anatomical outcomes [69] ABC Platform and Pipeline - Kodiak's ABC (Antibody Biopolymer Conjugate) Platform is designed for increased durability and efficacy in retinal medicines [28, 31] - Tarcocimab tedromer (KSI-301) is an anti-VEGF ABC designed for durability [29, 30] - KSI-501, a bispecific ABC medicine inhibiting both IL-6 and VEGF, has an IND filed and a Phase 1 study planned for 1H2023 [30, 81, 83] Market and Financial Position - Kodiak had $537 million in cash and marketable securities as of 3Q22 [102]